Arkitekt Ventures is an early stage venture firm, with a mission to improve and advance human health. We partner with exceptional founders building the next generation of Health & Bio companies.

Tia is the modern medical home for women. The company is trailblazing a new paradigm for women’s healthcare that treats women as whole people vs. parts or life stages.

Sollis Health offers best-in-class health care via 24/7 medical centers that handle emergencies, everyday checkups, and everything in between for the entire family.

First Close Partners backs venture funds owned by underrepresented managers helping them get to a “first close.” We invest in venture capital firms owned and operated by managers who are people women, people of color, LGBTQIA+, indigenous people, people with disabilities, and members of other groups that have been historically underrepresented, especially in the venture capital industry.

Nanite is a biotech company developing a new class of polymer nanoparticles for non-viral gene delivery. The company’s AI-driven platform SAYER™, combines high throughput experimental and computational methods to design delivery vehicles with tissue specificity for a variety of genetic medicines.

Cofertility is building a human-first fertility ecosystem that empowers everyone to own their own family-building timeline and journey.

Parsley Health is a holistic national medical practice, best described as the future of chronic care management.

HumanFirst is building the operational infrastructure to support decentralized trials and virtual care at home. Exited as M&A to ICON Plc (NASDAQ: ICLR)

Handspring Health provides quality and evidence-based mental healthcare for children.

CertifyOS is an API-first, UI agnostic, end-to-end network management platform for provider credentialing, enrollment, monitoring and licensing.

NOVOS is a human longevity company offering science-based and data-driven nutraceutical supplements and tests to address aging.

The Digital Medicine Society (DiMe) is a professional society serving individuals at the intersection of global healthcare and technology. DiMe supports the development of digital medicine through international interdisciplinary collaboration, research, teaching, and the promotion of best practices.

MediVis is bringing augmented reality, computer vision and machine learning to the operating room.

Canaery is an early stage biotechnology company engaged in developing a revolutionary ultra wide-band chemical sensor and analytics network.

Culina Health is a personalized, tech-enabled nutrition platform powered by registered dietitians to help you prioritize the way you want to live.

QSimulate revolutionizes industry R&D with innovative quantum simulations to make meaningful contributions to the drug discovery process.

Connie Health empowers older Americans via their Medicare consumer platform combining a tech-driven recommendation engine with local agents for personalized plan and healthcare navigation.

Elaborate is the platform doctors use to send lab results, providing patients with clarity on what the results mean and what to do next.

Paradromics is bringing to market a high-bandwidth brain machine interface, which will enable patients with debilitating disorders such as ALS or paralysis to reconnect with the outside world.

RAW IS EVERYTHING is a 100% organic, scientifically backed, skincare brand sold at national luxury retailer Bluemercury and clean beauty Follain stores. The company was conceived as part of a project/required curriculum for all first-year Harvard Business School students, and developed into a wellness brand featured in Glamour, New Beauty, Well + Good, Fast Company and The Huffington Post.

Private global investment vehicle. Direct investments in early-mid stage startups, as well as LP investments in venture, private equity and hedge funds. Active investments in US, Singapore, Europe and New Zealand.

Evaluated the commercial viability and scientific merit of the submissions for the $1M Prize. P4L's $1M Therapeutic Prize was established to advance discovery of treatments for ALS, a terminal neurodegenerative disorder.

ICE Angels is Australasia's largest angel investment network. Screening Committee Member for 2013.

Executed a genome-wide RNAi screen of 16,000+ genes to identify 245 novel genes with a role in neuronal cell fate. The results, published in top peer-reviewed journals and presented at national and international conferences, help further our understanding of neural fate specification.

Made key discovery that shed light in the current understanding of the pathogenesis of Mucolipidosis IV -a debilitating orphan disease.

Supported product adjustment and new product development of a wide variety of emulsion and solvent based acrylic polymers in response to customer needs.